• Facebook
  • Twitter
  • Events
  • News
  • Donate
Search
Hit enter to search or ESC to close
New Jersey Alliance for Clinical and Translational Science New Jersey Alliance for Clinical and Translational Science
  • Home
  • About
    • Mission
    • Membership
    • Affiliated Institutions
    • NJ ACTS Leadership
    • Cite the CTSA and Publications
    • CTSA Resources
    • Cores
  • Community
    • Our Services
    • Core Leadership & Advisory Council
    • Volunteering for a Clinical Trial FAQs
    • How to Find a Clinical Trial
    • Partnership & Innovation Funding Opportunities
    • COVID-19 Resources
  • Investigator Resources
    • Funding Opportunities
    • Biostatistics, Epidemiology, Research Design (BERD)
    • Informatics Services
    • Regulatory Knowledge & Support
    • Special Populations in Research
    • Team Science
    • Machine Learning
    • Biomarkers
    • COVID-19
    • ResearchMatch (RM)
    • Additional Resources
  • Education & Training
    • Workforce Development
    • Badges
    • Seminars, Workshops, Media Library
    • Diversity, Equity & Inclusion
    • Promoting STEM in High School and Earlier
    • Undergraduate Education and Training
    • Beyond Traditional Graduate Courses
    • NJ ACTS Collaborative Graduate Programs
  • KL2 & TL1
    • KL2 Mentored Career Development Awards
    • TL1 Predoctoral/Postdoctoral Training Awards
  • Clinical Trials Office
    • CTO About
    • OnCore
    • Solutions
    • Services
    • Manage Studies
    • Resources
  • Contact Us
    • NJ ACTS Newsletter
Select Page

Home / News / Pfizer’s COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults.

Pfizer’s COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults.

by William Jester | Sep 18, 2022 | Community, Covid, News

Pfizer’s COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults.

A new study is sure to add another layer of intrigue surrounding Pfizer’s COVID-19 pill Paxlovid. In the study, based on data collected from 109,000 patients at a large Israeli health system, the drug appeared highly effective in seniors. Researchers found that those 65 and older who got the drug shortly after infection had a roughly 75% lower chance of being hospitalized, a rate which is consistent with earlier results. However, those markedly decreased odds of hospitalization were not seen in the 40-64 age cohort, where researchers reported “no evidence of benefit.” That was the gist of their study writeup, which appeared in the New England Journal of Medicine, and the storyline was duly repeated countless times in mainstream media coverage. To read the full story.

 

Recent Posts

  • What to know about the upcoming flu season, vaccine
  • Beyond the Opioid Epidemic: Scientist Seeks to Develop non-Addictive Treatment for Pain.
  • Avoiding a “Tripledemic” This Winter.
  • Overdose deaths from fentanyl combined with stimulants increased 50-fold since 2010.
  • Flu season is approaching. Here’s what to expect in N.J.

Archives

  • 2023
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2022
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2021
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2020
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2019
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2018
    • December

Categories

  • Community (1,727)
  • Covid (945)
  • News (2,180)
  • Pilots (20)
Rutgers logo

THIS SITE

About

Membership

Community

Investigator Resources

Education & Training

News

Events

Contact

CONTACT US

New Jersey Alliance For Clinical and Translational Science (NJ ACTS)
Contact RU – info at 732-445-info(4636)


  • Facebook

  • Twitter

  • YouTube

  • LinkedIn

© 2019, New Jersey Alliance for Clinical and Translational Science (NJ ACTS). All rights reserved.| Privacy Policy

Rutgers, The State University of New Jersey, is an equal access/equal opportunity institution. Individuals with disabilities are encouraged to direct suggestions, comments, or complaints concerning any accessibility issues with Rutgers web sites to accessibility@rutgers.edu or complete the Report Accessibility Barrier or Provide Feedback Form.